Recent Biotech Buyouts at a Large Premium [Added APPX.]<pre> Acquired Premium Deal iHub Company Buyer to Market Value Date Reference KOSN BMY 233% $190M 5/08 <a href='read_msg.asp?message_id=29647147'>#msg-29647147</a> COLY PFE 167% $165M 11/07 <a href='read_msg.asp?message_id=24600805'>#msg-24600805</a> IOMI Intercell 147% $190M 5/08 <a href='read_msg.asp?message_id=29232165'>#msg-29232165</a> BTRX Stiefel 136% $150M 6/08 <a href='read_msg.asp?message_id=30201906'>#msg-30201906</a> ENCY PFE 118% $350M 2/08 <a href='read_msg.asp?message_id=26978155'>#msg-26978155</a> TRCA Ipsen 104% $660M 6/08 <a href='read_msg.asp?message_id=29795183'>#msg-29795183</a> SIRT GSK 85% $620M 4/08 <a href='read_msg.asp?message_id=28705020'>#msg-28705020</a> Jerini Shire *71% $520M 7/08 <a href='read_msg.asp?message_id=30452872'>#msg-30452872</a> MLNM Takeda 53% $8.8B 4/08 <a href='read_msg.asp?message_id=28365383'>#msg-28365383</a> APPX Fresenius †29% $940M 7/08 <a href='read_msg.asp?message_id=30498388'>#msg-30498388</a> *199% premium to volume-weighted price during preceding 3 months. †Premium reaches 63% if earn-out met.</pre>